Skip to Content

Janssen - Risperdal


Janssen - Risperdal

Janssen, a wholly-owned subsidiary of Johnson & Johnson, allegedly engaged in unfair and deceptive practices when it marketed its atypical antipsychotic drugs, Risperdal, Risperdal Consta, Risperdal M-Tab, and Invega, for treatments that were not approved by FDA ("off-label marketing"). As a result of the investigation, Janssen has agreed to change how it markets Risperdal and agreed to refrain from any false, misleading or deceptive promotion of the drugs, which was in violation of the Tennessee Consumer Protection Act. This was a multistate case.

Press Release

State Court Filings

This list includes only significant filings and is not intended to be a complete record of the matter.